Extendicare (TSE:EXE – Get Free Report) had its target price hoisted by equities research analysts at Royal Bank Of Canada from C$38.00 to C$39.00 in a research note issued to investors on Friday,BayStreet.CA reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target points to a potential upside of 18.83% from the stock’s previous close.
A number of other research analysts have also weighed in on EXE. TD raised their price target on shares of Extendicare from C$32.00 to C$39.00 and gave the company a “buy” rating in a research note on Monday, May 11th. National Bank Financial boosted their price objective on Extendicare from C$34.00 to C$40.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 27th. BMO Capital Markets increased their target price on Extendicare from C$30.00 to C$38.00 in a report on Wednesday, May 13th. Canaccord Genuity Group raised their target price on Extendicare from C$37.00 to C$44.00 and gave the company a “buy” rating in a research report on Monday. Finally, Desjardins lowered their price target on Extendicare from C$40.00 to C$39.00 and set a “buy” rating on the stock in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of C$37.00.
Read Our Latest Stock Analysis on Extendicare
Extendicare Price Performance
Extendicare (TSE:EXE – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported C$0.32 earnings per share (EPS) for the quarter. The business had revenue of C$611.04 million for the quarter. Extendicare had a net margin of 6.13% and a return on equity of 36.33%. On average, sell-side analysts anticipate that Extendicare will post 0.6134729 earnings per share for the current fiscal year.
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Read More
- Five stocks we like better than Extendicare
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
